GlassScriptPhysician profile
Barrett O Attarha
NPI 1164927950
$4,868.56
in general payments reported to CMS, 2019-2025
26 companies · $2,212 in 2025
The $2,212 reported for 2025 was more than what 81% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $96.95 · 2022: $254 · 2023: $463 · 2024: $1,842 · 2025: $2,212.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,991 · Travel and Lodging: $512 · Education: $13.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,991.37 |
| Travel and Lodging | $511.88 |
| Education | $13.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $853.91 | 2024-2025 | |
| Olympus America INC. | $814.68 | 2022-2025 | Single Use Electrosurgical Knife Kd-655, Evis X1 Video System Center, Visiglide |
| Cook Medical LLC | $402.03 | 2024 | Fusion |
| Janssen Biotech, INC. | $337.93 | 2024-2025 | Tremfya, Stelara, Simponi |
| Gilead Sciences, INC. | $331.42 | 2021-2024 | Livdelzi |
| Wilson Cook Medical Incorporated | $263.31 | 2024 | Fusion |
| Pfizer INC. | $225.35 | 2024-2025 | |
| Celltrion USA INC. | $214.78 | 2024-2025 | Vegzelma, Zymfentra |
| Medtronic, INC. | $213.30 | 2023 | Endoflip |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $187.71 | 2024-2025 | Relistor, Xifaxan, Trulance |
| Enterra Medical, INC. | $181.35 | 2025 | |
| Conmed Corporation | $163.14 | 2024-2025 | Conmed Hemostasis |
| Grifols Shared Services North America, INC. | $113.01 | 2025 | Prolastin-C Liquid |
| Takeda Pharmaceuticals U.S.A., INC. | $88.58 | 2024-2025 | Entyvio, Eohilia |
| Qol Medical, LLC | $60.58 | 2024-2025 | Sucraid, Sucraid |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $54.71 | 2024-2025 | Zenpep |
| Phathom Pharmaceuticals, INC. | $52.08 | 2025 | Voquezna |
| Boston Scientific Corporation | $49.71 | 2022-2025 | Speedband Superview Super 7, Exalt Model D |
| Ardelyx, INC. | $48.14 | 2024-2025 | Ibsrela |
| Lilly USA, LLC | $43.62 | 2025 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $43.22 | 2025 | Dupixent |
| Intercept Pharmaceuticals, INC. | $33.39 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $26.87 | 2025 | Iqirvo |
| Alnylam Pharmaceuticals INC. | $24.94 | 2025 | Givlaari |
| Madrigal Pharmaceuticals | $20.57 | 2024 | Resmetirom |
| Genzyme Corporation | $20.23 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barrett Attarha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.